A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2547-2559

  Müller, Nina ^a   Hartmann, Cord ^a   Genßler, Sabrina ^a   Koch, Joachim ^a   Kinner, Andrea ^a   Grez, Manuel ^a   Wels, Winfried S ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

epidermal growth factor receptor; ErbB; intrabody; intracellular antibody

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC TRANSMEMBRANE ANTIBODY; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 225; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 30; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER INHIBITION; CELL COMPARTMENTALIZATION; CELL SURFACE; CONTROLLED STUDY; GROWTH INHIBITION; HINGE REGION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SURFACE PROPERTY; TUMOR CELL; TUMOR GROWTH;

EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB; INTRABODY; INTRACELLULAR ANTIBODY;

ANTIBODIES, BISPECIFIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MEMBRANE; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; IMMUNOPRECIPITATION; IMMUNOTHERAPY; LUNG NEOPLASMS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED;

EID: 84896396085     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28585     Document Type: Article

References (48)

1. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
2. Ferguson KM, Berger MB, Mendrola JM, et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003; 11: 507-17.
3. Pines G, Kostler WJ, Yarden Y,. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 2010; 584: 2699-706.
4. Zandi R, Larsen AB, Andersen P, et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19: 2013-23.
5. Hynes NE, MacDonald G,. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21: 177-84.
6. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11.
7. Hartmann C, Müller N, Blaukat A, et al. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010; 29: 4517-27.
8. Sato JD, Kawamoto T, Le AD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1: 511-29.
9. Wels W, Beerli R, Hellmann P, et al. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 1995; 60: 137-44.
10. Beerli RR, Wels W, Hynes NE,. Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophys Res Commun 1994; 204: 666-72.
11. Shaki-Loewenstein S, Zfania R, et al. A universal strategy for stable intracellular antibodies. J Immunol Methods 2005; 303: 19-39.
12. Lo AS, Zhu Q, Marasco WA,. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 2008: 343-73.
13. Hyland S, Beerli RR, Barbas CF, et al. Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. Oncogene 2003; 22: 1557-67.
14. Loew R, Heinz N, Hampf M, et al. Improved Tet-responsive promoters with minimized background expression. BMC Biotechnol 2010; 10: 81.
15. Urlinger S, Baron U, Thellmann M, et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 2000; 97: 7963-8.
16. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-13.
17. Voelkel C, Galla M, Maetzig T, et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci U S A 2010; 107: 7805-10.
18. Stitz J, Buchholz CJ, Engelstadter M, et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000; 273: 16-20.
19. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995; 92: 7297-301.
20. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-5.
21. Maurer-Gebhard M, Schmidt M, et al. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 1998; 58: 2661-6.
22. Stamos J, Sliwkowski MX, Eigenbrot C,. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46265-72.
23. Montelione GT, Wuthrich K, Burgess AW, et al. Solution structure of murine epidermal growth factor determined by NMR spectroscopy and refined by energy minimization with restraints. Biochemistry 1992; 31: 236-49.
24. Whitelegg NR, Rees AR,. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng 2000; 13: 819-24.
25. Cardinale A, Biocca S,. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol Med 2008; 14: 373-80.
26. Messer A, Lynch SM, Butler DC,. Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. Expert Opin Biol Ther 2009; 9: 1189-97.
27. Beerli RR, Wels W, Hynes NE,. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994; 269: 23931-6.
28. Deshane J, Siegal GP, Alvarez RD, et al. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 1995; 96: 2980-9.
29. Beerli RR, Wels W, Hynes NE,. Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies. Breast Cancer Res Treat 1996; 38: 11-7.
30. Fiebiger E, Story C, Ploegh HL, et al. Visualization of the ER-to-cytosol dislocation reaction of a type I membrane protein. EMBO J 2002; 21: 1041-53.
31. Frank R,. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports-principles and applications. J Immunol Methods 2002; 267: 13-26.
32. Brandt O, Dietrich U, Koch J,. Solid-supported peptide arrays in the investigation of protein-protein and protein-nucleic acid interactions. Curr Chem Biol 2009; 3: 171-9.
33. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-67.
34. Lener M, Horn IR, Cardinale A, et al. Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras. Eur J Biochem 2000; 267: 1196-205.
35. Cardinale A, Filesi I, Biocca S,. Aggresome formation by anti-Ras intracellular scFv fragments. The fate of the antigen-antibody complex. Eur J Biochem 2001; 268: 268-77.
36. Yi KS, Chung JH, Lee YH, et al. Inhibition of the EGF-induced activation of phospholipase C-gamma1 by a single chain antibody fragment. Oncogene 2001; 20: 7954-64.
37. Sano R, Reed JC,. ER stress-induced cell death mechanisms. Biochim Biophys Acta, in press.
38. Healy SJ, Gorman AM, Mousavi-Shafaei P, et al. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 2009; 625: 234-46.
39. Ellgaard L, Ruddock LW,. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep 2005; 6: 28-32.
40. Liu G, Shang Y, Yu Y,. Induced endoplasmic reticulum (ER) stress and binding of over-expressed ER specific chaperone GRP78/BiP with dimerized epidermal growth factor receptor in mammalian cells exposed to low concentration of N-methyl-N′-nitro-N-nitrosoguanidine. Mutat Res 2006; 596: 12-21.
41. Bjorge JD, Paterson AJ, Kudlow JE,. Phorbol ester or epidermal growth factor (EGF) stimulates the concurrent accumulation of mRNA for the EGF receptor and its ligand transforming growth factor-alpha in a breast cancer cell line. J Biol Chem 1989; 264: 4021-7.
42. Soderquist AM, Carpenter G,. Glycosylation of the epidermal growth factor receptor in A-431 cells. The contribution of carbohydrate to receptor function. J Biol Chem 1984; 259: 12586-94.
43. Jannot CB, Beerli RR, Mason S, et al. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 1996; 13: 275-82.
44. Sunada H, Magun BE, Mendelsohn J, et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 1986; 83: 3825-9.
45. Sorkin A, Goh LK,. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2009; 315: 683-96.
46. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996; 15: 254-64.
47. Alvarez RD, Barnes MN, Gomez-Navarro J, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 2000; 6: 3081-7.
48. Russell SJ, Peng KW, Bell JC,. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-70.